Cafepharma Today

May 16 2025 - Novo CEO to depart as obesity drugmaker’s challenges rise
Novo CEO to depart as obesity drugmaker’s challenges rise
BioMarin expands enzyme expertise with $270M Inozyme buy
Amgen could owe Regeneron more than $400M after defeat in cholesterol drug antitrust suit
Eli Lilly collaborates with Rznomics on hearing loss treatment in $1.3 billion pact
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Synergy Pharmaceuticals Files IND for SP-333, a Developmental Drug for Gastrointestinal Diseases
Yahoo
Wednesday, September 12, 2012 - 11:34am
tags:
SP-333, Synergy Pharmaceuticals, gastrointestinal
Acadia: A Big Move Into Parkinson's Disease Psychosis Results
Seeking Alpha
Wednesday, September 12, 2012 - 11:33am
tags:
Acadia, Parkinson's Disease Psychosis, pimavanserin, Amarin
Experimental drug curbs smokers' nicotine cravings
Reuters
Wednesday, September 12, 2012 - 11:32am
tags:
smoking cessation, nicotine cravings, GSK, GSK598809
2-Star Stocks Poised to Plunge: Neurocrine Biosciences?
Motley Fool
Wednesday, September 12, 2012 - 11:31am
tags:
Neurocrine Biosciences
Why Risk Is Always Relative in Biotech
Motley Fool
Wednesday, September 12, 2012 - 11:30am
tags:
imetelstat, Geron, stem cells, breast cancer
Cell Therapeutics soars 24% on EU drug launch
Marketwatch
Tuesday, September 11, 2012 - 1:25pm
tags:
Europe, Cell Therapeutics, Pixuvri, non-Hodgkin's lymphoma
Dynavax: The BioRunUp Trade Into An FDA Panel
TheStreet.com
Tuesday, September 11, 2012 - 1:20pm
tags:
FDA, Dynavax, Heplisav, vaccines, hepatitis B
Ironwood: FDA Approval Makes the Price Right for This Pharma Stock
Motley Fool
Tuesday, September 11, 2012 - 1:19pm
tags:
Ironwood, FDA, Linzess
FDA to fast track Atox Bio's flesh-eating bacteria treatment
Reuters
Tuesday, September 11, 2012 - 1:14pm
tags:
FDA, Atox Bio, flesh-eating bacteria, necrotizing soft tissue infections, AB103
Merck's insomnia drug shows positive results
Marketwatch
Tuesday, September 11, 2012 - 1:12pm
tags:
insomnia, Merck, suvorexant
Novartis Chair: Winning Friends & Influencing Courts?
Pharmalot
Tuesday, September 11, 2012 - 1:11pm
tags:
Novartis, Daniel Vasella
The Top 5 Big Pharmaceuticals And Their Patent Cliffs
Seeking Alpha
Tuesday, September 11, 2012 - 12:33pm
tags:
patents, patent cliff, GSK, Novartis, Pfizer, Roche
Pfizer's Pipeline Could Push Stock 20% Higher By 2014
Seeking Alpha
Tuesday, September 11, 2012 - 12:02pm
tags:
Pfizer, Athersys
Drugmakers 'could free $33 bln of working capital'-analysts
Reuters
Tuesday, September 11, 2012 - 12:00pm
tags:
Pfizer, Roche, Sanofi, Merck
Will Medivation Be Twice as Good at Half the Price?
Motley Fool
Tuesday, September 11, 2012 - 11:59am
tags:
Medivation
Pfizer-J&J Alzheimer drug fails to stop mental decline but may slow brain plaque, studies find
Yahoo/AP
Tuesday, September 11, 2012 - 11:57am
tags:
Pfizer, JNJ, Alzheimer's disease, bapineuzumab
Merck: The Januvia Surge
Seeking Alpha
Tuesday, September 11, 2012 - 11:56am
tags:
Januvia, Merck, diabetes
"Better Than Nothing" Doesn't Cut It for Zalicus
Motley Fool
Tuesday, September 11, 2012 - 10:46am
tags:
Zalicus, Synavive, rheumatoid arthritis
AstraZeneca: Will New Drugs And CEO Reward Investors?
Seeking Alpha
Tuesday, September 11, 2012 - 10:44am
tags:
AstraZeneca, Roche, Pfizer, Forest Labs, Cubist Pharmaceuticals
Amarin Sees With 2030 Vision
Motley Fool
Tuesday, September 11, 2012 - 10:43am
tags:
Amarin, Vascepa

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.